Biogen Expands Kidney Disease Portfolio with Key Data Presentations at ERA and ATC
Event summary
- Biogen will present 14 abstracts on its nephrology portfolio at the ERA and ATC congresses in June 2026.
- Data includes new post-hoc analyses from the VALIANT study for EMPAVELI and Phase 2 felzartamab trial results.
- Presentations cover C3 glomerulopathy, primary IC-MPGN, and antibody-mediated rejection in kidney transplants.
- EMPAVELI's sustained efficacy and safety over one year in C3G and IC-MPGN patients will be highlighted.
The big picture
Biogen is reinforcing its position in nephrology with a dual-pronged strategy of expanding EMPAVELI's clinical profile and advancing felzartamab through late-stage trials. The focus on rare kidney diseases aligns with broader industry trends toward targeted therapies for underserved patient populations. Success in these areas could bolster Biogen's commercial portfolio beyond its core neurology focus.
What we're watching
- Clinical Validation
- Whether the sustained efficacy data for EMPAVELI in C3G and IC-MPGN can support broader approvals or label expansions.
- Pipeline Progress
- The pace at which felzartamab advances through Phase 3 trials for antibody-mediated rejection in kidney transplants.
- Commercial Strategy
- How Biogen leverages these data to differentiate its nephrology portfolio in a competitive market.
Related topics